Technology Description

This nano-drug is a long duration slow drug release technology for the treatment of tuberculosis including multiple drug resistant (MDR) and extremely drug resistant (XDR) tuberculosis (TB). This nano-drug anti-TB formulation would help shift from nine months of daily dose to only twice or thrice a month dose for nine months or less.

Applications

The drug would be used for tuberculosis control programs and would be of value to healthcare industry.

Benefits

• Oral drug gives independence to the patient to use the drug and does not require a skilled person to administer the drug.
  
• Sustained release for 10-15 days allows maintenance of therapeutic levels of drug in the relevant organs and blood minimising the hassle of daily dose.
  
• Daily dose linked non-compliance is leading to unabated rise in MDR and XDR and related morbidity and mortality along with cost burden on healthcare providers.
  
• The oral sustained release anti-TB drug would improve logistics making it suitable for global TB control programs.
  

Contact details:

Information Manager
Email: timeis@ficci.com